NCT00611598|Completed
Loading search results
Sponsor study identifier
observational
218
1 country
1
Study Start
February 11, 2003
Actual (reported)Primary Completion
March 24, 2023
Actual (reported)Study Completion
March 24, 2023
Actual (reported)The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. We hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final. We will analyze your blood cells and DNA to measure the changes in several genes that we believe may be involved in lung cancer. We also want to evaluate the capacity for your DNA to repair itself.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 24, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 11, 2003
Actual (reported)January 28, 2008
Actual (reported)February 11, 2008
Actual (reported)March 24, 2023
Actual (reported)March 24, 2023
Actual (reported)To conduct a pilot study of the role of DNA repair in lung cancer subjects with high genetic risk - those with a second primary lung cancer - compared to subjects with only one lung cancer.
conclusion of the study
To determine the association between cellular DNA repair and genetic alterations in DNA repair and associated pathways.
conclusion of the study
second primary lung cancer
single primary lung cancer
Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
MSKCC Clinic
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
* 30 ml. Blood in heparinized, green top tubes. * Fresh tumor or normal tissue, when available. * Tissue or cells from routine bronchoscopy, when available.
Irene Orlow, PhD
Memorial Sloan Kettering Cancer Center
218 participants (actual enrollment reported by the registry).
First Submitted
January 28, 2008
First Posted
February 11, 2008
Study Start
February 11, 2003
Actual (reported)ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 24, 2023
Actual (reported)Study Completion
March 24, 2023
Actual (reported)Last Updated
March 29, 2023
Record last verified: 2023-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: